Medicare Spending Growth Won't Trigger IPAB Cost Reduction Plan
Executive Summary
Threat of Independent Payment Advisory Board action to lower drug spending in Medicare alleviated for another year. Estimated spending growth in the program does not reach targets that would prompt cuts.
You may also be interested in...
Part D Coverage Gap Discounts Deepened To 70% In Budget Bill
Change, which could have multi-billion dollar impact on some large companies over 10 years, is framed as way to lower premiums in Medicare Part D.
Medicare Cuts Could Come From HHS In 2019 With No IPAB In Sight
There is a 'fair' likelihood that the Independent Payment Advisory Board will be called on to propose spending cuts to Medicare, effective in 2019, the CMS chief actuary says. And if there is no IPAB in existence, HHS will assume responsibility.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.